Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002343 · ClinicalTrials.gov registry record · Phase 4
A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS
A Phase 4 study, sponsored by Pharmacia.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00002343 is a Phase 4 study that has completed, run by Pharmacia. The registered enrollment target is 200 participants.
The verdict
NCT00002343, a Phase 4 study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to examine the effect of combination therapy in preventing or delaying the incidence of MAC bacteremia in this patient population.
Interventions
- DRUG Rifabutin
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002343
The ClinicalTrials.gov registry entry for NCT00002343 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifabutin is the first listed.
NCT00002343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002343 about?
NCT00002343 is a clinical study titled "A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS". To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to examine the effect of combination therapy in preventing or delaying the incidence of MAC bacteremia in this patie...
What is the current status of trial NCT00002343?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants.
What interventions are being tested in trial NCT00002343?
The interventions under investigation include: Rifabutin (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002343?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.